Prostate News Archive
22-Jul-2006
Biomira Stimuvax(R) (L-BLP25) Prostate Cancer Study Results Published (CNW Group via Yahoo! Finance)
Biomira Inc. , today announced publication of study results showing that Stimuvax, formerly known as BLP25 Liposome Vaccine or L-BLP25, could slow rising prostate Specific Antigen levels in some post-surgical prostate cancer patients, potentially delaying the need for initiation of androgen deprivation therapy . A New Diagnostic Tool For Prostate Cancer And How A "bigger" Chromosome 8 Can Predict Poorer Outcomes In Prostate (Medical News Today)
According to the World Health Organization there are about 250,000 new cases of prostate cancer every year but, when caught in time, the disease has a cure rate of over 90%. The problem is that the current methods of disease testing are still associated with too many misdiagnoses. [click link for full article] Watchful Waiting on Prostate Cancer (KABC-TV Los Angeles)
The purpose of detecting prostate cancer is to catch it while it's easy to cure. But now some younger patients are chosing not to immediately get the traditional treatment for the disease. And they say it's a scary choice. Analysis: Prostate Drug for Alzheimer's? (RedNova)
By ED SUSMAN Voyager Pharmaceutical Corp.'s investigational drug -- commonly used to treat prostate cancer -- received mixed results Wednesday from its phase 2 study in the treatment of men and women with mild-to-moderate Alzheimer's disease. The Prostate Cancer Center at Roswell Park Cancer Institute (WIVB Buffalo)
Roswell Park Cancer Institute offers a full range of treatment options for patients with prostate cancer. New diagnostic tool for prostate cancer (News-Medical-Net)
According to the World Health Organization there are about 250,000 new cases of prostate cancer every year but, when caught in time, the disease has a cure rate of over 90%. Biomira Stimuvax(R) (L-BLP25) Prostate Cancer Study Results Published (FinanzNachrichten)
EDMONTON, July 20 /PRNewswire-FirstCall/ -- Biomira Inc. ( Nachrichten ) (Nasdaq Global Market:BIOM) (TSX:BRA), today announced publication of study results showing that Stimuvax(R), formerly known as BLP25 Liposome Vaccine or L-BLP25, could slow rising Prostate Specific Antigen (PSA) levels in some post-surgical prostate cancer patients, potentially delaying the need for initiation of androgen A Spiritual Craft (Lexington Herald-Leader)
John Fisher can feel the prayers for him. Every day, Fisher goes into his computer room and lays a hand on a red, white and blue quilt hanging there. It was made for him six years ago by strangers in California and sent to him in Cedar Hill, Texas, while he was hospitalized with prostate cancer. Biomira's Stimuvax Could Benefit Prostate Cancer Patients (RedNova)
Biomira has released study results showing that Stimuvax, formerly known as BLP25 Liposome Vaccine, could slow rising prostate specific antigen levels in some post-surgical prostate cancer patients.
Back to Prostate News Archive
